Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1273 booster effectiveness against COVID-19 breakthrough infection in hemodialysis patients
2021-004608-17Phase 4Completed
- Sponsor
- AZ Sint-Jan Brugge
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AZ Sint-Jan Brugge. Primary endpoints: Incidence rate of breakthrough infections and Severity of breakthrough infections. Started Aug 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-004608-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004608-17.